Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.

Amplification of the ERBB2 oncogene at 17q12 is clinically the most relevant genetic aberration in breast cancer and several studies have linked ERBB2 activation to poor clinical outcome. The development of targeted antibody-based therapy for ERBB2-overexpressing tumors and the possible role of ERBB2 as a predictor of chemotherapy treatment response have further emphasized the essential role of ERBB2 in breast cancer. Here, we performed a detailed characterization of the molecular events occurring at the ERBB2 amplicon in primary breast tumors. Analysis of the amplicon structure in 330 breast tumors by fluorescence in situ hybridization to a tissue microarray revealed a 280-kb common region of amplification that contains 10 transcribed sequences, including eight known genes. The expression levels of these 10 transcripts were determined in 36 frozen samples of grade-matched ERBB2-amplified and -nonamplified (as determined by fluorescence in situ hybridization) primary breast tumors by using quantitativereal-time reverse transcriptase-polymerase chain reaction. A highly significant association between amplification and expression levels was observed for six of these genes, including ERBB2 and two uncharacterized hypothetical proteins, MGC9753 and MGC14832. These results support the recent findings on the influence of copy number on gene expression levels and highlight novel genes that might contribute to the clinical behavior of ERBB2-amplified breast tumors.

[1]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[2]  O. Monni,et al.  New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.

[3]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[4]  J W Gray,et al.  Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Wahl,et al.  Molecular dissection of mammalian gene amplification: new mechanistic insights revealed by analyses of very early events. , 1992, Mutation research.

[6]  Y. Yazaki,et al.  Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. , 1997, Cancer research.

[7]  R. Espinosa,et al.  Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  I. Wistuba,et al.  Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. , 2000, Cancer genetics and cytogenetics.

[9]  S. Paik,et al.  HER-2 and choice of adjuvant chemotherapy in breast cancer. , 2001, Seminars in oncology.

[10]  P. Basset,et al.  Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. , 1995, Genomics.

[11]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[12]  Y. Chen,et al.  Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. , 2000, Cancer research.

[13]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[15]  J. Kononen,et al.  Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. , 2000, Cancer research.

[16]  J. Guan,et al.  Association of Grb7 with Phosphoinositides and Its Role in the Regulation of Cell Migration* , 2002, The Journal of Biological Chemistry.

[17]  G. Wahl,et al.  Recent progress in understanding mechanisms of mammalian DNA amplification , 1989, Cell.

[18]  C. Hudis,et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.

[19]  G. Clark.  Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? , 1998, Journal of the National Cancer Institute.

[20]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays , 1999, Nature Genetics.

[21]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. D’Eustachio,et al.  The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.

[24]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[25]  G. Hostetter,et al.  Improved procedure for fluorescence in situ hybridization on tissue microarrays. , 2001, Cytometry.

[26]  K. Kohn,et al.  Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. , 2000, Journal of the National Cancer Institute.

[27]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[28]  David E. Misek,et al.  The Hepatocyte Nuclear Factor 3 α Gene, HNF3α (FOXA1), on Chromosome Band 14q13 Is Amplified and Overexpressed in Esophageal and Lung Adenocarcinomas , 2002 .

[29]  G. Wishart,et al.  Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 , 1993 .